Across TCGA pan-cancer cohorts, IGHV3-23 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGHV3-23 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGHV3-23 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3-23 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where IGHV3-23 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.705	1.000	.005	31	view →
PDAC	OS	Quartile	All	0.482	0.234	.007	18	view →
CCRCC	OS	Tertile	All	0.969	0.798	.011	9	view →
UCEC	DFS	Median	All	0.932	1.000	.022	6	view →
HNSC	OS	Median	III,IV	1.000	0.946	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGHV3-23 tumor-vs-normal RNA expression · all IGHV3-23 data types